Cilostazol is a prescription blood-flow drug used primarily to treat intermittent claudication, the cramping leg pain that forces people with peripheral artery disease to stop walking. It is one of only two medications approved in the United States specifically for that purpose, and the clinical evidence behind it is substantially stronger than for the other option. But cilostazol’s pharmacology gives it a surprisingly broad reach beyond leg pain, and researchers have spent decades exploring its potential in stroke prevention, coronary stent maintenance, wound healing, and even cognitive decline.
How Cilostazol Works
Cilostazol blocks an enzyme called phosphodiesterase III, which raises levels of a signaling molecule inside platelets and blood vessel walls. The downstream effects are multiple: blood vessels relax and widen, platelets become less sticky and less likely to clump, triglyceride levels drop, HDL (“good”) cholesterol rises, and the smooth muscle cells that line artery walls slow their overgrowth.1PubMed Central. The vascular effects of cilostazol That combination of vasodilation, antiplatelet activity, and lipid improvement is unusual for a single drug and helps explain why cilostazol keeps turning up in research on vascular problems well beyond its original indication.
Intermittent Claudication and Walking Distance
The most established use of cilostazol is for people with peripheral artery disease (PAD) who experience cramping, aching, or fatigue in their legs when they walk. Narrowed arteries cannot deliver enough blood to working muscles, so pain forces the person to stop. Cilostazol reliably extends both the distance someone can walk before pain starts and the total distance they can manage before they have to stop.
In a large randomized trial, patients taking cilostazol increased their maximum walking distance by roughly 40 percent over 16 weeks, while the placebo group improved by about 13 percent.2PubMed. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease A separate multicenter trial found similar results: about a 35 percent increase in the distance walked before the onset of pain and a 41 percent increase in total walking distance.3PubMed. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Real-world data from a multi-center European study confirmed these gains hold outside the controlled trial setting, with pain-free walking distance climbing by a median of about 285 meters at three months and 387 meters at six months in patients aged 50 to 74.4PubMed Central. Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease That same study found the benefit was less clear in patients 75 and older, a useful detail for older adults wondering whether the drug is worth trying.
How Cilostazol Compares to Other Claudication Drugs
The only other oral drug commonly used for claudication is pentoxifylline, which has been on the market longer but has weaker evidence behind it. A head-to-head trial found that cilostazol increased maximum walking distance by about 54 percent from baseline after 24 weeks, while pentoxifylline managed 30 percent, a result that was statistically indistinguishable from placebo.5PubMed. A comparison of cilostazol and pentoxifylline for treating intermittent claudication A network meta-analysis pooling data across multiple trials echoed those findings: cilostazol outperformed pentoxifylline on both maximum and pain-free walking distance.6PubMed Central. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis
Interestingly, naftidrofuryl oxalate, a drug available in parts of Europe but not the U.S., may actually outperform cilostazol on walking distance outcomes. A systematic review ranked naftidrofuryl first for both maximum and pain-free walking distance, with cilostazol second and pentoxifylline a distant third.7British Journal of Surgery. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication For people in countries where naftidrofuryl is available, this ranking is worth discussing with a doctor. In the U.S., cilostazol remains the strongest pharmacological option for claudication.
Secondary Stroke Prevention
After surviving a stroke, the pressing concern is preventing a second one. Aspirin is the default antiplatelet drug for this purpose, but cilostazol has shown strong results in head-to-head comparisons, particularly in East Asian populations where much of the research has been conducted.
A meta-analysis covering 18 randomized trials found that cilostazol reduced recurrent ischemic stroke by about 31 percent and any stroke (including hemorrhagic) by about 36 percent compared to control treatments.8BMJ. Cilostazol for secondary stroke prevention: systematic review and meta-analysis A separate systematic review comparing cilostazol directly to aspirin found a 33 percent lower risk of any stroke with cilostazol.9PubMed Central. The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis Most of these trials specifically excluded patients whose strokes were caused by blood clots forming in the heart, so the evidence applies mainly to non-cardioembolic strokes, the type caused by diseased arteries rather than irregular heart rhythms.
Lower Bleeding Risk Than Aspirin
One of cilostazol’s most clinically meaningful advantages in stroke prevention is its gentler bleeding profile. The same meta-analysis of 18 trials found that cilostazol roughly halved the risk of brain hemorrhage compared to aspirin or other controls, and also significantly reduced major bleeding events.10BMJ. Cilostazol for secondary stroke prevention: systematic review and meta-analysis Another meta-analysis focusing specifically on the cilostazol-versus-aspirin comparison confirmed reduced risks of intracranial hemorrhage and any bleeding with cilostazol.11Journal of Stroke and Cerebrovascular Diseases. Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis
This matters in practice because brain hemorrhage is one of the most feared complications of antiplatelet therapy. In one trial, brain bleeding events occurred in seven aspirin-treated patients but only one cilostazol patient.12The Lancet Neurology. Cilostazol versus aspirin for secondary prevention of stroke A nationwide cohort study comparing cilostazol with clopidogrel (another common antiplatelet drug) after ischemic stroke found similar rates of brain hemorrhage, gastrointestinal bleeding, and major bleeding between the two drugs.13PubMed Central. Comparison of long-term efficacy and safety between cilostazol and clopidogrel in chronic ischemic stroke: a nationwide cohort study Cilostazol, then, appears to offer stroke prevention on par with or better than aspirin, with meaningfully less bleeding risk. Guidelines in Japan and some other Asian countries already recommend it as a first-line option after non-cardioembolic stroke, though it remains off-label for this purpose in the West.
Slowing the Narrowing of Brain Arteries
Intracranial atherosclerosis, the buildup of plaque inside arteries within the skull, is a major cause of stroke worldwide and is especially common in Asian populations. Cilostazol appears to slow or even reverse this narrowing. In a double-blind trial, progression of symptomatic artery narrowing occurred in only about 7 percent of cilostazol-treated patients versus nearly 29 percent on placebo, while regression (actual widening of the artery) was more common in the cilostazol group.14PubMed. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis A meta-analysis pooling several studies confirmed cilostazol was superior to aspirin in preventing the progression of intracranial stenosis.15PubMed Central. Effects of cilostazol on the progression and regression of symptomatic intracranial artery stenosis The mechanism likely involves cilostazol’s ability to restrain smooth muscle cell proliferation and protect the endothelial lining of blood vessels, effects that go beyond simple platelet inhibition.
After Coronary Stenting
When a narrowed coronary artery is opened with a stent, two antiplatelet drugs (usually aspirin plus clopidogrel) are given to prevent the stent from clotting shut. Adding cilostazol as a third agent, a strategy called triple antiplatelet therapy, has been studied extensively in patients receiving drug-eluting stents. A meta-analysis of eight randomized trials found that triple therapy cut the odds of restenosis (the artery re-narrowing inside the stent) by about half compared to standard dual therapy, and also reduced the need for repeat procedures.16PubMed Central. The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis An updated meta-analysis confirmed these benefits without finding any increase in all-cause death, heart attack, stent clotting, or major bleeding.17PubMed. Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation
A large registry study (the DECREASE registry) reinforced these findings in a real-world setting, showing that triple therapy with cilostazol significantly reduced heart attacks and stent thrombosis over 12 months compared to dual therapy, with no increase in major bleeding.18American Heart Journal. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation The catch is that adding a third antiplatelet drug always raises theoretical bleeding concern, so this approach tends to be reserved for patients considered at higher risk of stent failure.
Wound Healing and Diabetic Foot Ulcers
Because cilostazol improves blood flow to the limbs, researchers have tested whether it helps wounds heal in patients with poor circulation. In a study of patients who had bypass surgery for severe limb ischemia, those taking cilostazol healed their wounds faster: the median healing time was about 45 days versus 78 days in the comparison group, with one-year wound healing rates of roughly 92 percent versus 81 percent.19PubMed. Cilostazol Improves Wound Healing in Patients Undergoing Open Bypass for Ischemic Tissue Loss
In people with diabetes, foot ulcers are a common and dangerous complication. A randomized controlled trial found that adding cilostazol to standard wound care significantly reduced ulcer size over three months, and complete healing occurred in 30 percent of patients on standard care alone compared to 65 percent receiving cilostazol with a selenium supplement and 43 percent receiving cilostazol combined with selenium.20PubMed Central. Impact of Cilostazol versus Cilostazol and Selenium Combination on The Healing of Diabetic Foot Ulcer Patients While more research is needed, the logic is straightforward: better blood flow to a wound site means better delivery of oxygen and immune cells, which helps tissue repair.
Cognitive Decline and Dementia Risk
This is an area where the evidence is still maturing, but the signals are encouraging. A systematic review and meta-analysis found that cilostazol users had a modestly but statistically significant lower risk of dementia compared to non-users.21PubMed Central. Effects of cilostazol on cognitive function and dementia risk: A systematic review and meta-analysis The hypothesis is that cilostazol protects the brain’s small blood vessels, which are damaged in vascular dementia. Animal studies support this idea: in a mouse model of chronic brain hypoperfusion, cilostazol reduced damage to the neurovascular unit and improved working memory.22Scientific Reports. Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion
No one is prescribing cilostazol for dementia prevention yet, and the effect size in human data is small. But for patients already taking cilostazol for PAD or stroke prevention, the potential cognitive upside is a notable secondary benefit. Clinical trials specifically designed to test cilostazol’s cognitive effects are underway.
Endothelial Protection and Anti-Inflammatory Effects
Beyond its antiplatelet and vasodilatory actions, cilostazol appears to protect the endothelium, the thin layer of cells lining blood vessels. In a double-blind trial of patients with acute cerebral ischemia, cilostazol improved a standard measure of how well blood vessels dilate in response to increased blood flow, a sign of healthier endothelial function.23PubMed Central. Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique Lab studies show the drug dials down inflammatory signaling pathways in endothelial cells, reducing the expression of molecules that attract immune cells and promote plaque formation.24Cardiovascular Research. Cilostazol inhibits cytokine-induced nuclear factor-κB activation via AMP-activated protein kinase activation in vascular endothelial cells These anti-inflammatory properties help explain why cilostazol’s benefits show up across so many different vascular beds, from leg arteries to brain arteries to coronary stents.
Raynaud’s Phenomenon
Raynaud’s phenomenon causes fingers and toes to turn white or blue and go numb in response to cold or stress, because small blood vessels spasm shut. In patients with scleroderma-related Raynaud’s, a small study found that cilostazol treatment significantly reduced both the number of daily episodes and the duration of each episode, while also improving the patients’ own assessment of how severe their symptoms were. Notably, none of the patients developed digital ulcers during treatment.25PubMed. Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients A separate study showed that cilostazol increased the diameter of larger arm arteries in patients with both primary and secondary Raynaud’s, though it did not improve microvascular flow or symptoms in all groups.26The American Journal of Cardiology. Effects of cilostazol in patients with Raynaud’s syndrome The evidence here is thin, based on small studies, and cilostazol is not a first-line treatment for Raynaud’s. But it represents an option for patients who have not responded well to calcium channel blockers.
Diabetic Nephropathy
A randomized, double-blind, placebo-controlled trial in patients with diabetic kidney disease found that cilostazol reduced the progression of albuminuria (protein leaking into the urine, a marker of kidney damage) in a dose-dependent manner. The researchers suggested this effect occurred through improvement of glomerular hyperfiltration, an early stage of diabetic kidney injury where the kidneys filter blood at an abnormally high rate.27Journal of Diabetes and Treatment. Effect of Cilostazol as an Antiplatelet Agent on Diabetic Nephropathy with Macroalbuminuria This is still an early finding and cilostazol is not used routinely for kidney protection, but it adds to the picture of a drug whose vascular effects extend beyond just opening up arteries.
The Heart Failure Warning
Despite its broad vascular benefits, cilostazol carries a black box warning — the most serious type of FDA safety label. It is contraindicated in patients with heart failure of any severity. Other drugs that block the same enzyme have been linked to reduced survival in heart failure patients, and although cilostazol itself has not been shown to worsen outcomes in heart failure, the FDA applies the warning based on the class effect.28PubMed Central. The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database This is not a theoretical footnote. Doctors will check for heart failure before prescribing cilostazol, and patients need to report any new symptoms like swelling, shortness of breath, or unexpected weight gain.
Common Side Effects and How to Manage Them
The standard dose is 100 mg taken twice daily, at least half an hour before or two hours after breakfast and dinner (food increases absorption, which can spike side effects). The most frequent complaints are headache, diarrhea, dizziness, and a feeling that the heart is racing. Headache is the main reason people quit the drug early.29PubMed. Clinical efficacy and safety of cilostazol: a critical review of the literature
A practical workaround is to start at a lower dose and ramp up. In a study of diabetic patients, starting at a lower dose before titrating up to the full 100 mg twice daily dropped the rate of headache-related discontinuation from about 24–29 percent down to 8 percent.30Diabetes & Metabolism Journal. Titration with an Initially Lower Dose Increased Compliance of Cilostazol A similar escalation approach in acute stroke patients also significantly reduced headache and treatment discontinuation.31Internal Medicine. Escalation Regimen of Cilostazol for Acute Brain Infarction If your doctor prescribes cilostazol and you are worried about side effects, asking about a gradual dose increase is a reasonable conversation to have.
Drug Interactions Worth Knowing About
Cilostazol is broken down in the liver by enzymes that also process many other drugs. When the antibiotic erythromycin (a strong inhibitor of one of those enzymes) was given alongside cilostazol, the blood levels of cilostazol roughly doubled.32PubMed. Effects of CYP3A inhibition on the metabolism of cilostazol Other drugs that inhibit the same liver enzyme, including ketoconazole, itraconazole, diltiazem, and grapefruit juice, can have a similar effect. When these interactions are unavoidable, doctors often halve the cilostazol dose to 50 mg twice daily. Omeprazole and other proton pump inhibitors also affect cilostazol metabolism through a different liver enzyme. If you take cilostazol alongside multiple medications, a pharmacist review of potential interactions is genuinely useful here, not just boilerplate advice.
Diabetic Peripheral Neuropathy
Nerve damage in the feet and hands is another consequence of diabetes that involves small blood vessel injury. Animal research has shown that cilostazol can restore normal pain responses in diabetic rats, calming overactivated immune cells in the spinal cord and correcting abnormal expression of sodium channels in nerve tissue. Even low doses were enough to reverse abnormal sensitivity to touch.33Frontiers in Pharmacology. Cilostazol Ameliorates Peripheral Neuropathic Pain in Streptozotocin-Induced Type I Diabetic Rats These are animal findings, not clinical proof, but they suggest a biological rationale for testing cilostazol in human diabetic neuropathy. Given that effective treatments for painful diabetic neuropathy are limited and often involve drugs with significant sedation or dependency risks, even preliminary leads in this space attract attention.